Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790876 | 0.90 | DPP4 (0.42) | STSABCB1GPR119KDM4EPKM | |
| SCHEMBL6236453 | 0.89 | DPP4 (0.35) | SMYD2DPP4HSD17B10 | |
| SCHEMBL6233716 | 0.89 | DPP4 (0.35) | SMYD2DPP4HSD17B10 | |
| SCHEMBL30218143 | 0.85 | BCHE (0.33) | KDM4ESMYD2MAPK1DPP4 | |
| SCHEMBL29007758 | 0.85 | ABCB1 (0.38) | STSABCB1GPR119KDM4EPKM | |
| SCHEMBL17948125 | 0.85 | ABCB1 (0.38) | STSABCB1GPR119KDM4EPKM | |
| SCHEMBL1769258 | 0.85 | ABCB1 (0.38) | STSABCB1GPR119KDM4EPKM | |
| SCHEMBL13759689 | 0.85 | ABCB1 (0.40) | STSABCB1GPR119KDM4EPKM | |
| SCHEMBL31224155 | 0.85 | ABCB1 (0.40) | STSABCB1GPR119KDM4EPKM | |
| SCHEMBL31224004 | 0.84 | ABCB1 (0.37) | STSABCB1GPR119KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4396187-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| WO-2023034290-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | STS 4062/4885ABCB1 539/4885GPR119 2742/4885 |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | STS 4062/4885ABCB1 539/4885GPR119 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.